RESUMO
A group of 37 postmenopausal women ingested mestranol (MEE) 20 ug daily per 90 days. Cervical mucus, vaginal citology, endometrial biopsy, 17 beta estradiol (E-2) low density lipoprotein-cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C), were determined in all of them before (phase I) and after such treatment (phase II). Besides, the relieve of vasomotor symptoms, fernlike cristallization and pyknotic nuclei cells, increase and 3/4 of the endometrial samples showed proliferation, in phase II. Endogenous circulating E-2 was not disturbed regardless MEE treatment and inverse relationship was attained on circulating lipoproteins, while LDL-C decrease (p = 0.01), HDL-C increase (p = 0.001), after comparing phase I vs. phase II. Chlormadinone acetate (2 mg/day/3 days) was administered at the end of the MEE treatment to avoid endometrial estrogenic persistence. Current studies should be enlarged to support the usage of new dose and regimen of mestranol replacement therapy.
Assuntos
Terapia de Reposição de Estrogênios , Mestranol/administração & dosagem , Pós-Menopausa , Colesterol/sangue , Endométrio/efeitos dos fármacos , Endométrio/patologia , Feminino , Humanos , Mestranol/uso terapêutico , Pessoa de Meia-Idade , Pós-Menopausa/efeitos dos fármacos , Pós-Menopausa/metabolismoRESUMO
Un grupo de 37 mujeres postmenopáusia recibieron mestranol (MEE) 20 ug/d/90 d. En cada una se tomaron muestras de moco cervical citología vaginal, biopsia de endometrio y sangre para medir 17 beta estradiol (E-2), fracciones de baja (LDL-C) y alta HDL-C densidad lipoproteica del colesterol antes (fase I) y después de ese tratamiento (fase II). Además de suprimir la sintomatología vasomotora, el moco endocervical y las células vaginales cariopicnóticas aumentaron y 3/4 de las biopsias presentaron proliferación en la fase II. No se produjo cambio en la concentración de estrógenos natural. La fracción LDL-C disminuyó (p=0.01) y la HLD-C aumentó (p=0.001) al comparar las fases I y II. Acetato de clormadinona fue administrado 2 mg/d/3 d para descamar el endometrio hacia el final del tratamiento con MEE. Para fundamentar esta dosis estrogénica y el nuevo régimen es necesario aumentar la casuística
Assuntos
Pessoa de Meia-Idade , Humanos , Feminino , Estrogênios/metabolismo , Estrogênios/uso terapêutico , Mestranol/administração & dosagem , Mestranol/uso terapêutico , Terapia de Reposição de Estrogênios/métodos , Terapia de Reposição de EstrogêniosRESUMO
A comparative clinical trial of two combined oral contraceptives differing only in estrogen type and dosage was conducted at the Centro de Investigaciones Hideyo Noguchi in Merida, Yucatan, Mexico. The trial was designed to determine the differences between Norinyl 1 + 50 (Syntex) and Norinyl 1 + 35 (Syntex) in rates of discontinuation and frequency of selected side-effects which might contribute to method discontinuation. Three hundred women were randomly assigned to either the Norinyl 1 + 35 group or to the Norinyl 1 + 50 group and follow-up visits were scheduled at 1, 4, 8 and 12 months after admission. In the Norinyl 1 + 35 group, more women experienced an increase in intermenstrual bleeding (primarily staining and spotting) (p less than 0.05), breast discomfort (p less than 0.05) and nausea than in the Norinyl 1 + 50 group. There was a significantly higher discontinuation rate for personal reasons, such as desired change of method and method not needed, among the women taking Norinyl 1 + 35 (p less than 0.05). The largest number of discontinuations comprised women discontinuing for menstrual problems in both groups. The life-table total discontinuation rate at 12 months was 52.0 for the Norinyl 1 + 35 group and 50.7 for the Norinyl 1 + 50 group. The lost-to-follow-up rates at 12 months were 17.8 for the Norinyl 1 + 35 group and 22.8 for the Norinyl 1 + 50 group.
Assuntos
Anticoncepcionais Orais Combinados/efeitos adversos , Anticoncepcionais Orais Sintéticos/efeitos adversos , Mestranol/efeitos adversos , Noretindrona/efeitos adversos , Adolescente , Adulto , Anticoncepcionais Orais Combinados/administração & dosagem , Anticoncepcionais Orais Sintéticos/administração & dosagem , Combinação de Medicamentos , Feminino , Humanos , Mastite/induzido quimicamente , Mestranol/administração & dosagem , México , Estudos Multicêntricos como Assunto , Náusea/induzido quimicamente , Noretindrona/administração & dosagem , Cooperação do Paciente , Distribuição Aleatória , Hemorragia Uterina/induzido quimicamenteAssuntos
Anticoncepcionais Orais Combinados/farmacologia , Anticoncepcionais Orais/farmacologia , Eritrócitos/efeitos dos fármacos , Hematócrito , Anticoncepcionais Orais Combinados/administração & dosagem , Relação Dose-Resposta a Droga , Contagem de Eritrócitos , Feminino , Humanos , Dispositivos Intrauterinos , Mestranol/administração & dosagem , Mestranol/farmacologia , Noretinodrel/administração & dosagem , Noretinodrel/farmacologia , Gravidez , Distribuição Aleatória , Cremes, Espumas e Géis Vaginais/farmacologiaAssuntos
Etinilestradiol/farmacologia , Menstruação/efeitos dos fármacos , Mestranol/farmacologia , Noretindrona/farmacologia , Administração Oral , Adolescente , Adulto , Combinação de Medicamentos , Etinilestradiol/administração & dosagem , Feminino , Humanos , Mestranol/administração & dosagem , Noretindrona/administração & dosagem , Fatores de TempoRESUMO
PIP: Experience with the oral contraceptive Ovostat (.1 mg mestranol and 1 mg lynestrenol) in 324 women (5714 cycles) is reported. Only 1 pregnancy was observed, in a patient who had forgotten several pills. Side effects included headache (11 patients), nervousness (5 patients), amenorrhea (4 patients), and chloasma (3 patients). Breakthrough bleeding and spotting were rare. Cervical mucus (samples on Days 9-11 and 13-15 in 50 women) was uniformly inhospitable to sperm: low viscosity, negative Farn test, constant pH. Endometrial biopsy showed tissue typical of "suppressed" endometrium.^ieng
Assuntos
Anticoncepcionais Orais/administração & dosagem , Linestrenol/administração & dosagem , Mestranol/administração & dosagem , Adulto , Muco do Colo Uterino/efeitos dos fármacos , Ensaios Clínicos como Assunto , Anticoncepcionais Orais/efeitos adversos , Tolerância a Medicamentos , Endométrio/efeitos dos fármacos , Feminino , Humanos , Linestrenol/efeitos adversos , Linestrenol/farmacologia , Mestranol/efeitos adversos , Mestranol/farmacologia , México , Hemorragia Uterina/induzido quimicamenteAssuntos
Anticoncepcionais Orais/administração & dosagem , Mestranol/administração & dosagem , Noretindrona/administração & dosagem , Adulto , Estudos de Avaliação como Assunto , Serviços de Planejamento Familiar , Feminino , Humanos , Menstruação/efeitos dos fármacos , Mestranol/efeitos adversos , Noretindrona/efeitos adversos , GravidezRESUMO
PIP: 135 women who had had at least 1 child were treated with 80 mg of mestranol and 1 mg of lynestrenol on a 22 day on, 6 day off basis for a total of 800 cycles of observation. Follow-up was done monthly. Endometrial and cervical biopsies were done and levels of pregnanediol in the urine were tested. Cycles were between 25-31 days with an average of 28. Flow averaged 3 days' duration and was slight in 53.1% of the cycles, normal in 39.3% and heavy in 2.1%. 48.3% of the cycles were characterized by no dysmenorrhea, 35.7% by slight, 11% by moderate, and 1.8% by severe. Incidence of spotting and breakthrough bleeding was slight. Side effects were also slight; nausea was present in 7.6% of the cycles, hypogastric tension in 6.6%, chloasma in 5.9%, and severe headache in 4.3%. Headaches were the only side effect reported with any regularity. No pregnancies occurred. Only 14 patients discontinued. Test results indicated that under medication the amount of pregnanediol diminished, the endometrium modified its ovulatory functions, the cervical mucus lost it ability to crystallize or stretch, and vaginal shedding was slightly modified.^ieng